A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Cervical Cancer|Gastric/Gastroesophageal Junction Adenocarcinoma|Microsatellite Stable Colorectal Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck|Carcinoma, Renal Cell|Urothelial Carcinoma|Pancreatic Adenocarcinoma|Melanoma|Ovarian Neoplasms|Triple Negative Breast Neoplasms
Interventions: DRUG: BMS-986340|DRUG: BMS-936558-01|DRUG: Docetaxel
Sponsor: Bristol-Myers Squibb